Outcome
    Moderate Evidence

    Lion's Mane for Neuroprotection

    Neuroprotective claims for lions mane rest on cell and animal models, not human outcomes.

    Overview

    Neuroprotective claims for lions mane rest on cell and animal models, not human outcomes.

    Verdict

    Insufficient evidence

    How It Works

    Hericenones and erinacines upregulate NGF and BDNF and reduce beta-amyloid toxicity and neuroinflammation in preclinical models.

    Dosing & Protocol

    Typical dose

    Recommended dose
    Not established; neuroprotective effects are demonstrated only in animal models, with no human trial measuring neuroprotective outcomes
    Expected timeframe
    Not established

    Protocol

    form
    Not applicable
    duration
    Not applicable
    co factor
    Evidence is insufficient. Animal work is extensive and often cited: lion's mane extracts and erinacines reduce amyloid-beta plaque burden, oxidative stress and neuronal loss in rodent models of Alzheimer disease, Parkinson disease and ischaemic stroke, apparently via NGF pathway stimulation. None of this has been tested in humans as a neuroprotective endpoint. The single positive human trial measured cognitive scores in mild cognitive impairment over 16 weeks - a symptomatic measure over a short period, not disease modification, and the benefit disappeared after stopping, which argues against structural protection. No trial has measured brain volume, biomarkers of neurodegeneration, or progression to dementia. The gap between rodent neuroprotection and human outcomes has claimed a great many candidate compounds.
    titration
    Not applicable
    starting dose
    Not applicable as an established treatment

    Evidence

    What the studies say

    Preclinical data are consistent across several models, but the only supportive human trial is a small 16-week study in mild cognitive impairment. No trial has assessed neurodegenerative disease progression.

    Peripheral Nerve Regeneration Following Crush Injury to Rat Peroneal Nerve by Aqueous Extract of Medicinal Mushroom Hericium erinaceus

    Score: 6/10
    2011
    rct
    n=50

    Wong KH, Naidu M, David RP +2 more

    Aqueous extract of Hericium erinaceus promoted peripheral nerve regeneration following crush injury in rats.

    View source

    Safety

    Caveats

    What has real human evidence for reducing dementia risk: blood pressure control in midlife, treating hearing loss, physical activity, not smoking, limiting alcohol, managing diabetes and staying socially engaged. These are unglamorous and effective. Progressive cognitive change needs medical assessment - reversible causes including B12 deficiency, thyroid disease, depression and sleep apnoea are treatable, and lion's mane should not delay evaluation. Safety: generally well tolerated at 1-3 g/day over months, with mild gastrointestinal upset most common. Skin rash and rare respiratory allergic reactions have been reported; avoid with mushroom allergy. Possible mild antiplatelet and glucose-lowering effects mean caution with anticoagulants, antiplatelets and diabetes medication, and stopping two weeks before surgery. No established upper intake level and no long-term safety data beyond about a year. No safety data in pregnancy or breastfeeding - avoid in both, and in children.

    Less likely to help if

    Everyone: no human neuroprotective outcome data exist.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.